Immunoglobulin half-molecules and process for producing hybrid antibodies

• US 4,470,925 A
• Filed: 10/04/1983
• Issued: 09/11/1984
• Est. Priority Date: 05/05/1982
• Status: Expired due to Term

• Current Assignee: Dade Behring, Inc. (Siemens AG)
• Original Assignee: E. I. du Pont de Nemours and Company (Corteva, Inc.)
• Inventors: Auditore-Hargreaves, Karen
• Primary Examiner(s): Schain, Howard E.
• Application Number:
  US06/538,962
• Time in Patent Office: 343 Days
• Field of Search: 260/112 B, 260/112 R, 424/85, 424/88, 435/188
• US Class Current: 530/387.3
• CPC Class Codes: A61K 47/68 the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• CPC Class Codes: G01N 33/531 Production of immunochemical test materials
• CPC Class Codes: G01N 33/577 involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens; G01N33/53 - G01N33/576 take precedence
• CPC Class Codes: G01N 33/6854 Immunoglobulins
• CPC Class Codes: G01N 33/94 involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
• CPC Class Codes: Y10S 530/83 Plasma; serum
• CPC Class Codes: Y10S 530/866 involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Abstract

A process for preparing covalent hybrid antibodies is provided. These antibodies are obtained by the ordered covalent hybridization of intact immunoglobulin molecules. The generation of half-molecules from different IgG antibodies by reductive or S-sulfonation selective cleavage is followed by the ordered association of the different half-molecules. The pure covalent hybrid antibodies as new substances are also provided along with IgG half-molecules.

Claims

1. A substantially pure covalent hybrid antibody consisting essentially of two different heavy chain-light chain half-molecules, wherein the first of said half-molecules provides a binding site for a first antigen and the second of said half-molecules provides a chemically different binding site for the first or a second antigen;

and wherein said half-molecules are bonded to each other through disulfide linkage.

2. The covalent hybrid antibody of claim 1 wherein the first and second half-molecules provide chemically different binding sites for different antigens.

3. The covalent hybrid antibody of claim 2 wherein the first half-molecule provides a binding site for an analyte and the second half-molecule provides a binding site for an indicator.

4. The covalent hybrid antibody of claim 3 wherein the analyte is selected from the group consisting of protein, hormone, drug, vitamin, enzyme, antibody, polysaccharide, bacterium, protozoa, fungi, virus, cell and tissue antigens.

5. The covalent hybrid antibody of claim 3 wherein the indicator is selected from the group consisting of enzyme and aggregating substance.

6. A process for preparing covalent hybrid antibodies comprising the steps of:

(A) selectively cleaving a first immunoglobulin molecule which is an antibody to a first antigen into its heavy chain-light chain half-molecules by sulfitolysis of the inter-heavy chain disulfide linkage to produce S-sulfonated half-molecules;

(B) selectively cleaving a second immunoglobulin molecule which is an antibody to the first or a second antigen into its heavy chain-light chain half-molecules by reduction of the inter-heavy chain disulfide linkage to produce reduced half-molecules; and

(C) combining the S-sulfonated half-molecules from step (A) with the reduced half-molecules from step (B).

7. The process of claim 6 wherein the reduced half-molecules are produced by reduction of the inter-heavy chain disulfide linkage.

8. The process of claim 6 wherein the reduced half-molecules are produced by sulfitolysis of the inter-heavy chain disulfide linkage followed by reduction.

9. The process of claim 8 wherein the sulfitolysis reaction comprises the steps of:

(A) mixing an immunoglobulin molecule with sodium sulfite and 5,5'"'"'-dithiobis(2-nitrobenzoic acid);

(B) incubating in a nonoxidizing atmosphere; and

(C) separating the protein products.

10. The process of claim 7 wherein the reduced half-molecules are produced by reduction of immunoglobulin molecule bound to an immobilized receptor.

11. The process of claim 10 wherein the receptor is antigen bonded to a support.

12. The process of claim 10 wherein the receptor is Protein A bonded to a support.